Alvin J. Siteman Cancer Center

Agendia Spotlights the Future of Personalized Breast Cancer Care at 2022 San Antonio Breast Cancer Symposium

Retrieved on: 
Monday, December 5, 2022
Research, Women, Genetics, Clinical Trials, Biotechnology, Health, Consumer, Science, Oncology, UPMC Hillman Cancer Center, Physician, Prognosis, Recurrence, 2009 Davis Cup, Hematology, Pediatric Hematology and Oncology, CT, Johns Hopkins University, MD, MD Anderson Cancer Center, University, American Journal of Clinical Oncology, Gene expression profiling, Transcriptome, Patient, Alvin J. Siteman Cancer Center, Science, Research, Biology, Genomics, Breast cancer, Professor, Assistant, Blueprint, Neoplasm, IDEAL, Woman, Oncology, UCSF, Surgeon, Behavior, Journal, Marie Cassidy, Growth, 2022 European Space Agency Astronaut Group, UPMC, NET, FLEX, Associate, Risk, Medical imaging, MammaPrint

Agendia, Inc. , a leader in gene expression profiling for early-stage breast cancer, received acceptance for all six abstract submissions that will help guide the future of personalized cancer care and will be presented at the 2022 San Antonio Breast Cancer Symposium (SABCS).

Key Points: 
  • Agendia, Inc. , a leader in gene expression profiling for early-stage breast cancer, received acceptance for all six abstract submissions that will help guide the future of personalized cancer care and will be presented at the 2022 San Antonio Breast Cancer Symposium (SABCS).
  • Three of the studies Agendia will present are based on its FLEX trial, the largest real-world evidence database of patients with early-stage breast cancer.
  • The research derived from our FLEX trial is a key example of the type of advancements in breast cancer Agendia is helping to fuel.
  • These critical discoveries will improve the future of personalized care for all women with breast cancer, including those who are often underrepresented in genomic studies, said William Audeh, MD, Chief Medical Officer at Agendia.

AltruBio to Present New Phase 1b Data Evaluating Neihulizumab (ALTB-168) in Patients with Steroid-Refractory or Treatment-Refractory Acute Graft-Versus-Host-Disease at the 64th ASH Annual Meeting 2022

Retrieved on: 
Thursday, November 3, 2022
Company, Private Securities Litigation Reform Act, Therapy, Alvin J. Siteman Cancer Center, SAN, Society, Biotechnology, GLOBE, Saint Francis Hospital & Medical Center, Population, Cell, Safety, Assistant professor, IND, Poster, Medical College of Wisconsin, ASH, Graft-versus-host disease, Inflammation, Ulcerative colitis, Assistant, Psoriasis, News, Autoimmunity, Patient, Pharmacokinetics, Pharmaceutical industry, Vaccine

Clinical trial investigator, Sameem Abedin, M.D., Assistant Professor, Medical College of Wisconsin, Cancer Center, Froedtert Hospital Medical will be on-site to present the data.

Key Points: 
  • Clinical trial investigator, Sameem Abedin, M.D., Assistant Professor, Medical College of Wisconsin, Cancer Center, Froedtert Hospital Medical will be on-site to present the data.
  • Neihulizumab (ALTB-168) is an immune checkpoint enhancer that regulates T cell homeostasis.
  • ALTB-168 is being evaluated in a Phase 1 study ( NCT03327857 ) to establish the pharmacokinetics, pharmacodynamics, safety and efficacy profiles in patients with steroid-refractory or treatment refractory acute graft-versus-host disease (SR/TR-aGVHD).
  • The Company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by law.

JDRF Announces the Appointment of David M. Harlan, MD, as Director of the JDRF Center of Excellence in New England

Retrieved on: 
Thursday, June 16, 2022
Biomedical Research, Doctor of Philosophy, Harvard University, Joslin, Education, Industry, T1D, JDRF, Medical school, Harvard Medical School, School, Jackson Laboratory, News, National Cancer Institute, Efficiency, Research, University of Massachusetts, Hospital, Disease, University of Massachusetts Medical School, Alvin J. Siteman Cancer Center, U.S. News & World Report, University, Health, Volunteering, Biomedical sciences, Joslin Diabetes Center, Twitter, HSCI, Diabetes, Multimedia, NIH, Pharmaceutical industry, MD, Facebook, Instagram

To accomplish this, JDRF has invested more than $2.5 billion in research funding since our inception.

Key Points: 
  • To accomplish this, JDRF has invested more than $2.5 billion in research funding since our inception.
  • We collaborate with academic institutions, policymakers, and corporate and industry partners to develop and deliver a pipeline of innovative therapies to people living with T1D.
  • For more information, please visit jdrf.org or follow us on Twitter (@JDRF), Facebook (@myjdrf), and Instagram (@jdrfhq).
  • UMass Chan Medical School , one of five campuses of the University of Massachusetts system, comprises the T.H.

Aravive to Host Key Opinion Leader Symposium on May 11, 2022

Retrieved on: 
Thursday, May 5, 2022
TAM, Cancer, Gynecologic Oncology (journal), Division, KOL, Stanford University, GLOBE, Company, Alvin J. Siteman Cancer Center, Radiation therapy, Platinum, European Commission, GAS6, NYU Langone Health, Arav, Associate, Metastasis, Vanderbilt University Medical Center, FDA, Therapy, Ovarian cancer, AXL, Pancreas, Washington University in St. Louis, Clinical trial, Royal commission, Pharmaceutical industry, Flour, Medicine

HOUSTON, May 05, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announced that it will host a Key Opinion Leader (KOL) Symposium on the GAS6-AXL signaling pathway and the Companys lead drug candidate, batiraxcept.

Key Points: 
  • HOUSTON, May 05, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announced that it will host a Key Opinion Leader (KOL) Symposium on the GAS6-AXL signaling pathway and the Companys lead drug candidate, batiraxcept.
  • Senior management will also provide updates on Aravives clinical development programs.
  • The event will take place on May 11, 2022, from 8:00 am ET to 12:00 pm ET and will include a live and archived webcast at: https://ir.aravive.com/events-and-presentations .
  • Batiraxcept has been granted Fast Track Designation by the U.S. FDA and Orphan Drug Designation by the European Commission in platinum-resistant recurrent ovarian cancer.

ACCC Releases New Resources to Support Quality Care Delivery for Patients with Ovarian Cancer

Retrieved on: 
Wednesday, March 16, 2022
Association, MD, Gaps, Quality of life, Education, Navigation, Cancer, Patient, Hospital, Fibroadenoma, Knowledge, Washington University School of Medicine, Risk, Alvin J. Siteman Cancer Center, Genetic testing, Geographic Locator Codes, Diagnosis, Learning, Barrier, Molecular biology, George Washington University School of Medicine & Health Sciences, Benchmarking, Biomarker, Blog, Woman, Genetic counseling, Population, Social media, Barnes-Jewish Hospital, ACCC, Disease, Birth control, Pharmaceutical industry, Ovarian cancer

Through the Barriers to Quality Care in Ovarian Cancer , a collaborative, multi-year, expert-led initiative, ACCC has developed actionable resources for improvement in the delivery of comprehensive, quality ovarian cancer care, including process-focused recommendations.

Key Points: 
  • Through the Barriers to Quality Care in Ovarian Cancer , a collaborative, multi-year, expert-led initiative, ACCC has developed actionable resources for improvement in the delivery of comprehensive, quality ovarian cancer care, including process-focused recommendations.
  • These practical resources support providers in identifying gaps in quality care delivery for ovarian cancer, learning from peer quality improvement experiences, and benchmarking progress toward optimal care for this patient population.
  • A review article developed for this initiative, Improving the quality of care for patients with advanced epithelial ovarian cancer: Program components, implementation barriers, and recommendations , published inCancer(November 2021) addresses core components of quality ovarian cancer care, including care coordination and patient education, prevention and screening, diagnosis and initial management, treatment planning, disease surveillance, equity in care, and quality of life.
  • Yet, as identified through the ACCC initiative, care delivery barriersranging from insufficient access to genetic counseling and specialists in gynecologic cancers to fragmentation in healthcare systemsoften impede consistent widespread integration into ovarian cancer care delivery.

Moleculin Announces Updated Preliminary Safety Data for Annamycin in Its Three Phase 1 Clinical Trials for Acute Myeloid Leukemia and Metastases of Soft Tissue Sarcoma

Retrieved on: 
Tuesday, January 18, 2022
Securities Exchange Act of 1934, Antimetabolite, Anthracycline, LinkedIn, Private Securities Litigation Reform Act, SEC, Patient, AML, U.S. Securities and Exchange Commission, US Foods, Cancer, European, Face, AST, Clinical trial, Incidence, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Form 10-K, COVID-19, Cardiotoxicity, T-cell lymphoma, Hair loss, Safety, Risk, DLT, ALT, MTD, Lung, Cleveland Clinic, Company, Alvin J. Siteman Cancer Center, STS, Food, FDA, Principal, Brain, Cleveland, Forward-looking statement, Review, Doxorubicin, Toxicity, Drug Quality and Security Act, Index (publishing), Securities Act of 1933, Virus, CEO, Acute myeloid leukemia, Quality of life, Neoplasm, Twitter, Security (finance), Hair, Patient safety, Terminology, Pharmaceutical industry, Facebook, Annamycin

Two of the three clinical trials, as described more fully below, are ongoing and the data from those trials remain preliminary and are subject to change and future updates.

Key Points: 
  • Two of the three clinical trials, as described more fully below, are ongoing and the data from those trials remain preliminary and are subject to change and future updates.
  • The ongoing trials are both in the dose escalation phase (Phase 1) with the goal of determining the recommended Phase 2 dose (RP2D).
  • For more information about the Phase 1b/2 study evaluating Annamycin for the treatment of STS lung metastases, please visit clinicaltrials.gov and reference identifier NCT04887298.
  • Annamycin is currently in development for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases.

Study Confirms Nutrient's Role in Childhood Blood Cancer

Retrieved on: 
Wednesday, December 22, 2021
DNA, Laura, Organic acid, NYU Langone Health, Publishing, Doctor of Philosophy, National Institutes of Health, Patient, Lists of diseases, Cancer, Meat, Machine learning, Mouse, Bone marrow, Cell, Nature, National, Valine, New York State Department of Health, Venetoclax, Diet, NYU, Elias C. Aifantis, Protein, Leukemia, American Association, American Cancer Society, Gene, Association, Muscle, New York University Grossman School of Medicine, Department, Intelligentsia, Acute lymphoblastic leukemia, Alvin J. Siteman Cancer Center, Brain damage, Nucleotide, Research, NOTCH1, Hermann, Clinical trial, Lysine, Dietary supplement, Vaccine, Pharmaceutical industry, Pathology

The diet also reduced circulating blood cancer cells by at least half and in some cases to undetectable levels.

Key Points: 
  • The diet also reduced circulating blood cancer cells by at least half and in some cases to undetectable levels.
  • He cautions that dietary strategies alone for treating cancer have been tried for decades with little scientific evidence of any benefit.
  • The American Cancer Society estimates that more than 1,500 Americans, mostly children, die each year from T cell acute lymphoblastic leukemia.
  • Study co-investigator Aristotelis Tsirigos, PhD, serves as a scientific advisor to Intelligencia.AI in New York City, a software company that applies machine learning to cancer drug development.

Sierra Oncology Reports Baseline Ferritin Differentially Predicts Week 24 Transfusion Independence Response in Myelofibrosis Patients

Retrieved on: 
Monday, December 13, 2021
Biotechnology, General Health, Health, Clinical Trials, Oncology, Washington University School of Medicine, Primary myelofibrosis, Doctor of Philosophy, Symptoms of COVID-19, Cancer, Time, NASDAQ, GA, Anemia, Alvin J. Siteman Cancer Center, Patient, JAK, MD, ASH, Ruxolitinib, Society, Splenomegaly, Pharmaceutical industry, Surveying, Momelotinib, Sierra Oncology, MOMELOTINIB, SIERRA ONCOLOGY

Sierra Oncology, Inc. (NASDAQ: SRRA), a late-stage biopharmaceutical company on a mission to deliver targeted therapies that treat rare forms of cancer, today announced data from new retrospective analyses of the Phase 3 SIMPLIFY studies demonstrate baseline ferritin differentially predicts Week 24 Transfusion Independence Response for momelotinib and ruxolitinib in patients with myelofibrosis.

Key Points: 
  • Sierra Oncology, Inc. (NASDAQ: SRRA), a late-stage biopharmaceutical company on a mission to deliver targeted therapies that treat rare forms of cancer, today announced data from new retrospective analyses of the Phase 3 SIMPLIFY studies demonstrate baseline ferritin differentially predicts Week 24 Transfusion Independence Response for momelotinib and ruxolitinib in patients with myelofibrosis.
  • For patients with baseline ferritin between 90-650 ng/mL, momelotinib-treated patients had higher Week 24 TI-R than those treated with BAT [53% vs 22%, OR 2.27 (95% CI: 1.01,12.77); p=0.03099].
  • Future evaluation may be made in forthcoming clinical trials to further examine the correlation between ferritin and TI response.
  • Sierra Oncology is a late-stage biopharmaceutical company on a quest to deliver targeted therapies that treat rare forms of cancer.

New Drug Combo May Improve Family-donated Stem Cells as Blood Cancer Treatment

Retrieved on: 
Monday, December 13, 2021
Transplant, Doctor of Pharmacy, Rash, Lists of diseases, Graft-versus-host disease, NYU Langone Health, Alvin J. Siteman Cancer Center, Leukemia, Haematopoietic system, Arthritis, MSN, Adult, Abatacept, Patient, Society, Blood, Department, American Society of Hematology, Liver, Lymphatic system, Cell, Doctor of Science, NYU, Parent, Family, Woman, Department of Medicine – University of Pamplona, Assault, Akram al-Homsi, Kidney, Diarrhea, CAST, NP, MBA, Cyclophosphamide, Tacrolimus, Man, Doctor of Philosophy, Disease, Vomiting, Amgen, AbbVie, Nausea, Sibling, Vaccine, Pharmaceutical industry, Dentistry, Hematology, Asian Americans, MD, RN

Researchers say stem cell transplantation, especially from members of the same family, has transformed the treatment of leukemia, a disease that afflicts nearly a half-million Americans.

Key Points: 
  • Researchers say stem cell transplantation, especially from members of the same family, has transformed the treatment of leukemia, a disease that afflicts nearly a half-million Americans.
  • And although the treatment is successful for many, half of those who undergo the procedure experience some form of graft-versus-host disease (GvHD).
  • The rest (22 men and women, or 95 percent) remain cancer free more than five months after their transplant, with donated cells showing signs of producing new, healthy, and cancer-free blood cells.
  • Al-Homsi says abatacept is "more targeted" than mycophenolate mofetil and prevents immune T cells from becoming "activated," a necessary step before these immune cells can attack other cells.

Caris Life Sciences to Present at the 2021 San Antonio Breast Cancer Symposium

Retrieved on: 
Tuesday, December 7, 2021
Twitter, Precision medicine, Technology, Disease, Duke Cancer Institute, CCND1, Breast cancer, Androgen receptor, Wilms' tumor, TMB, Diagnosis, USC Norris Comprehensive Cancer Center, POA, Poster, Blood, Physician, Metastasis, ICI, Drug development, FGF4, Patient, Biomarker, Alvin J. Siteman Cancer Center, NCI, TME, Brown University, Tumor microenvironment, Artificial intelligence, Biopsy, MSI-H, CNA, Science, CBFB, American Securities, DNA, Cancer, FGF19, MBC, Biology, Research, IHC, NGS, KMT2D, Brain, Exome, Bone, Protein, Mutation, Senior, Triple-negative breast cancer, RNA, Pharmaceutical industry, Medical imaging, Dentistry

IRVING, Texas, Dec. 7, 2021 /PRNewswire/ -- Caris Life Sciences (Caris), the leading molecular science and technology company actively developing and delivering innovative solutions to revolutionize healthcare, announced today that it will present results at the San Antonio Breast Cancer Symposium (SABCS) that illustrate the potential impact of molecular profiling on the treatment of breast cancer.

Key Points: 
  • IRVING, Texas, Dec. 7, 2021 /PRNewswire/ -- Caris Life Sciences (Caris), the leading molecular science and technology company actively developing and delivering innovative solutions to revolutionize healthcare, announced today that it will present results at the San Antonio Breast Cancer Symposium (SABCS) that illustrate the potential impact of molecular profiling on the treatment of breast cancer.
  • Relationships between breast cancer metastases site and mutations detected by DNA next-generation sequencing were investigated using 12,464 breast cancer samples using Caris' Next-Generation Sequencing (NGS) technology.
  • Caris will present additional data from studies demonstrating the critical role of precision medicine and molecular profiling in the treatment of breast cancer.
  • Co-occurring biomarkers within TMB-H breast cancer warrant evaluation in prospective cohorts for response or resistance to ICI to help develop composite biomarkers in breast cancer.